BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1

Completed

Conditions: Neoplasms by Site

Interventions: Biological: Relatlimab
Biological: BMS-986213
Biological: Nivolumab

First Posted Date: 2013-10-23

Last Posted Date: 2025-03-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1499

Registration Number: NCT01968109

Locations: 🇺🇸
Local Institution - 0002, Portland, Oregon, United States
🇯🇵
Local Institution - 0052, Chuo-ku, Tokyo, Japan
🇺🇸
Local Institution - 0043, La Jolla, California, United States

and more 51 locations

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Cobimetinib

First Posted Date: 2013-08-23

Last Posted Date: 2024-12-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1163

Registration Number: NCT01928394

Locations: 🇺🇸
Local Institution - 0001, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0007, Portland, Oregon, United States
🇺🇸
Local Institution - 0002, Nashville, Tennessee, United States

and more 35 locations

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma
Unresectable Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Placebo

First Posted Date: 2013-08-22

Last Posted Date: 2022-03-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 142

Registration Number: NCT01927419

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

and more 18 locations

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Phase 3

Terminated

Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab

First Posted Date: 2013-07-03

Last Posted Date: 2021-07-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT01891643

Locations: 🇺🇸
Crescent City Research Consortium, LLC, Marrero, Louisiana, United States
🇺🇸
Illinois Cancercare, Pc, Peoria, Illinois, United States
🇺🇸
Memorial Cancer Institute, Hollywood, Florida, United States

and more 7 locations

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2013-07-01

Last Posted Date: 2015-11-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 356

Registration Number: NCT01890473

Locations: 🇺🇸
Physician Research Collaboration, Llc, Lincoln, Nebraska, United States
🇿🇦
Local Institution, George, Western Cape, South Africa
🇺🇸
Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States

and more 11 locations

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Asunaprevir

First Posted Date: 2013-06-26

Last Posted Date: 2013-11-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT01886599

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
New Orleans Center For Clinical Research, Knoxville, Tennessee, United States

Eliquis Regulatory Post Marketing Surveillance

Completed

Conditions: NonValvular Atrial Fibrillation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-25

Last Posted Date: 2017-10-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3335

Registration Number: NCT01885598

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Apixaban

First Posted Date: 2013-06-25

Last Posted Date: 2016-02-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT01885585

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Phase 4

Completed

Conditions: Anticoagulation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-24

Last Posted Date: 2019-11-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 557

Registration Number: NCT01884337

Locations: 🇮🇳
Local Institution, Pune, India

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Phase 4

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-24

Last Posted Date: 2019-08-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1217

Registration Number: NCT01884350

Locations: 🇬🇧
Local Institution, Tauton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy